- Breakthrough method ‘starves’ highly lethal cancer tumors and eradicates them
- Coronavirus protein found to cut off key immune pathway
- Safety of iPS platelet transfusion confirmed
- Married and high-education men are more likely to live longer than women
- Father and son won the Nobel Prize in medicine 40 years apart
- Scientists are trying to get mosquitoes to deliver vaccines to humans
BIONTECH: Mutant COVID-19 vaccine can be made in six weeks
BIONTECH: Mutant COVID-19 vaccine can be made in six weeks. BIONTECH: Confidence in the response to the virus mutation of the COVID-19 vaccine, a new vaccine can be made within six weeks.
On December 22, local time in Germany, the German biotechnology company BioNTech held an online press conference.
According to Agence France-Presse, at the press conference, Ugg Sain, the founder and CEO of Qide, said when talking about the mutation of the new coronavirus in the UK at the press conference, they did not know whether its vaccine would be effective. To deal with the mutant strains found in the UK, further research is needed, and I hope to confirm it in the next few weeks.
Ugg Sain mentioned that, in principle, the company can make a new vaccine against a new mutant virus within six weeks.
According to Ugg Sain, the variant found in the UK has 9 mutations. The virus “contains more than 1,000 amino acids, of which only 9 amino acids have changed, which means that 99% of the proteins are still the same.”
Ugg Sain said that because the protein on the variant is 99% identical to the previous epidemic strain, the company is still confident that the vaccine can still provide protection from a scientific point of view. He also mentioned that the company’s mRNA COVID-19 vaccine is relatively more likely to work.
On December 21, local time, Byentec’s COVID-19 vaccine obtained a conditional EU sales authorization. Prior to this, the vaccine was authorized for emergency use in the United Kingdom and the United States. According to the official BIONTECH, with the authorization of the 27 EU member states, its COVID-19 vaccine has now obtained conditional sales authorization, emergency use authorization or temporary authorization in more than 40 countries/regions. The region is undergoing a regulatory review, and more authorizations are expected in the coming weeks.